This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

China Probes Sanofi for Alleged Bribery

BEIJING -- Chinese authorities have launched an investigation against French drugmaker Sanofi (SNY) following a news report that accused the company of bribing hundreds of Chinese doctors in 2007.

An unnamed whistleblower told the Guangzhou-based, state-owned 21st Century Business Herald that the French company had paid 503 doctors a total of $274,000 to prescribe Sanofi products, disguising the payments as grants for research programs.

China's official Xinhua News Agency said Saturday that the Beijing municipal health bureau was teaming up with disciplinary authorities to look into the research programs and determine whether the payments were actually bribes.

Sanofi did not immediately respond to a request for comment.

According to the 21st Century Business Herald report, Sanofi said it took the claim "very seriously" and had started to investigate the allegations.

The investigation of Sanofi comes amid a crackdown by China's drug regulator on misconduct in the country's pharmaceutical market.

Last month, Chinese police detained four employees of British pharmaceutical manufacturer GlaxoSmithKline (GSK) on suspicion of paying bribes to doctors and hospitals to encourage them to prescribe medications.

In China's dysfunctional health system, low salaries and skimpy budgets drive doctors, nurses and administrators to make ends meet by accepting money from patients, drug suppliers and others. The practice has long been common knowledge.

Meanwhile, the Cabinet's planning agency is investigating production costs at 60 Chinese and foreign pharmaceutical manufacturers, according to state media, possible as a prelude to revising state-imposed price caps on key medications.

In the baby formula market, the government has fined six milk suppliers, including Mead Johnson (MJN) and New Zealand's Fonterra, a total of $108 million for price-fixing after an investigation that shook the country's fast-growing dairy market.

Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.99 -0.29%
FB $80.12 0.65%
GOOG $572.52 -0.20%
TSLA $199.20 -0.18%
YHOO $43.57 2.20%

Markets

DOW 18,116.53 -86.84 -0.48%
S&P 500 2,099.45 -8.33 -0.40%
NASDAQ 4,971.1970 -8.7040 -0.17%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs